Gene: PIK3CB

5291
P110BETA|PI3K|PI3KBETA|PIK3C1
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
protein-coding
3q22.3
Ensembl:ENSG00000051382 MIM:602925 Vega:OTTHUMG00000159893 UniprotKB:P42338
NC_000003.12
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.725e-1 (AD)  8.183e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12493155chr3:138681490 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SYNJ10.976
MAP2K40.976
PPP3CB0.973
CHIC10.973
HSPA12A0.972
TRIM370.972
NAPG0.971
COL4A3BP0.971
G3BP20.97
ATP6V1A0.969

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.486
HEY2-0.479
OR4F5-0.472
MYL3-0.467
RNF135-0.466
COPZ2-0.464
RAB13-0.462
RHOD-0.457
ASB4-0.455
CHST14-0.452

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00201CaffeineSmall Molecule58-08-2ApprovedTarget
DB05241XL765Small Molecule-InvestigationalTarget
ID Drug Name Action PubMed
C5696701-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one"1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one results in decreased activity of PIK3CB protein"21998291
C5696701-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one"1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one results in decreased activity of PIK3CB protein"21981714
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of PIK3CB mRNA"21354444|2269881
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of PIK3CB mRNA]"22698814
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine affects the activity of PIK3CB protein"18754654
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine affects the activity of PIK3CB protein"23318440
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased activity of PIK3CB protein"19509167|2012977
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of PIK3CB protein16179367
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased activity of PIK3CB protein20129775
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of PIK3CB mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3CB mRNA"27188386
C0275764-hydroxy-2-nonenal4-hydroxy-2-nonenal results in increased expression of PIK3CB mRNA19191707
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3CB mRNA"27188386
D017638Asbestos, Crocidolite"Asbestos, Crocidolite affects the expression of PIK3CB mRNA"17331233
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in decreased expression of PIK3CB mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene metabolite results in increased expression of PIK3CB mRNA26314263
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PIK3CB mRNA20064835|2010694
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of PIK3CB mRNA"19150397
C095105bexarotenebexarotene results in increased expression of PIK3CB mRNA16648578
C006780bisphenol Abisphenol A affects the expression of PIK3CB mRNA25181051
C005961bis(tri-n-butyltin)oxidebis(tri-n-butyltin)oxide results in increased expression of PIK3CB mRNA26314263
D002118CalciumPIK3CB protein affects the transport of Calcium11597992
C018021cobaltous chloridecobaltous chloride results in increased expression of PIK3CB mRNA26314263
D019327Copper SulfateCopper Sulfate results in decreased expression of PIK3CB mRNA19549813
D016572CyclosporineCyclosporine results in increased expression of PIK3CB mRNA25562108
C531198dactolisibdactolisib results in decreased activity of PIK3CB protein20129775
D003907DexamethasoneDexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of PIK3CB mRNA]27941970
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of PIK3CB mRNA17361019|2126653
C437392disodium quercetin-7,4'-disulfate"disodium quercetin-7,4'-disulfate results in decreased activity of PIK3CB protein"11931710
C118739entinostatentinostat results in increased expression of PIK3CB mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3CB mRNA"27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIK3CB mRNA22079256
D000431EthanolEthanol results in increased expression of PIK3CB mRNA20655511
C561695(+)-JQ1 compound(+)-JQ1 compound affects the expression of PIK3CB mRNA26397223
C104183LE 540LE 540 inhibits the reaction [Tretinoin results in increased expression of and results in increased activity of PIK3CB protein]16043647
D007854LeadLead affects the expression of PIK3CB mRNA28903495
D008748Methylcholanthrene[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PIK3CB mRNA23519560
C030957methylmercury IImethylmercury II results in increased expression of PIK3CB mRNA26314263
C406082monomethylarsonous acidmonomethylarsonous acid results in increased expression of PIK3CB mRNA22108045
C008548morinmorin results in increased expression of PIK3CB mRNA28689916
C558744N-(6-(6-chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo(d)thiazol-2-yl)acetamideN-(6-(6-chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo(d)thiazol-2-yl)acetamide results in decreased activity of PIK3CB protein21332118
C558744N-(6-(6-chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo(d)thiazol-2-yl)acetamideN-(6-(6-chloro-5-(4-fluorophenylsulfonamido)pyridin-3-yl)benzo(d)thiazol-2-yl)acetamide results in decreased activity of PIK3CB protein21612232
C571178NVP-BKM120NVP-BKM120 results in decreased activity of PIK3CB protein22653967
C025589ochratoxin Aochratoxin A metabolite results in increased expression of PIK3CB mRNA26314263
C025589ochratoxin Aochratoxin A results in increased expression of PIK3CB mRNA26314263
D010634PhenobarbitalPhenobarbital affects the expression of PIK3CB mRNA23091169
C522973PI103PI103 results in decreased activity of PIK3CB protein19584227
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of PIK3CB mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of PIK3CB mRNA22079256
D011794QuercetinQuercetin results in decreased activity of PIK3CB protein19814731
C059514resveratrolresveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CB protein]17550345
C059514resveratrolresveratrol results in decreased expression of PIK3CB mRNA25667456
C059514resveratrolresveratrol inhibits the reaction [Streptozocin results in decreased expression of PIK3CB mRNA]26071184
D013311Streptozocinresveratrol inhibits the reaction [Streptozocin results in decreased expression of PIK3CB mRNA]26071184
D013311StreptozocinStreptozocin results in decreased expression of PIK3CB mRNA26071184
C061133tamibarotenetamibarotene affects the expression of PIK3CB mRNA15498508
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of PIK3CB mRNA21632981
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PIK3CB mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to PIK3CB promoter]19654925
D013752TetracyclineTetracycline results in increased expression of PIK3CB mRNA16917069
D013755Tetradecanoylphorbol Acetate[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PIK3CB mRNA23519560
C504718TGX 221PIK3CB protein results in increased susceptibility to TGX 221 analog22588880
C504718TGX 221TGX 221 analog results in decreased activity of PIK3CB protein22588880
C504718TGX 221[TGX 221 analog results in decreased activity of PIK3CB protein] which results in decreased phosphorylation of AKT1 protein22588880
C504718TGX 221TGX 221 results in decreased activity of PIK3CB protein22556157|2258888
D014212TretinoinLE 540 inhibits the reaction [Tretinoin results in increased expression of and results in increased activity of PIK3CB protein]16043647
D014212TretinoinTretinoin results in decreased expression of PIK3CB mRNA15498508
D014212TretinoinTretinoin results in increased expression of and results in increased activity of PIK3CB protein16043647
D014212TretinoinTretinoin results in increased expression of PIK3CB mRNA16043647
C011559tributyltintributyltin results in increased expression of PIK3CB mRNA26314263
D014635Valproic AcidValproic Acid results in increased expression of PIK3CB mRNA23179753|2800136
C009687wortmanninwortmannin results in decreased activity of PIK3CB protein11931710
C510150ZSTK474ZSTK474 analog results in decreased activity of PIK3CB protein21882832
C510150ZSTK474ZSTK474 results in decreased activity of PIK3CB protein20129775

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI7479742  19380743  20713702  22402981  23397142  25241761  
25556234  26496610  27107012  
GO:0005524ATP binding-IEA-  
GO:0016301kinase activity-IDA25327288  
GO:00163031-phosphatidylinositol-3-kinase activity-IBA21873635  
GO:00163031-phosphatidylinositol-3-kinase activity-TAS-  
GO:0035004phosphatidylinositol 3-kinase activity-TAS21035500  
GO:00350051-phosphatidylinositol-4-phosphate 3-kinase activity-IBA21873635  
GO:0043560insulin receptor substrate binding-IEA-  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO:0052742phosphatidylinositol kinase activity-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0000187activation of MAPK activity-TAS10570282  
GO:0001935endothelial cell proliferation-IEA-  
GO:0001952regulation of cell-matrix adhesion-IMP25139353  
GO:0006468protein phosphorylation-IBA21873635  
GO:0006874cellular calcium ion homeostasis-IEA-  
GO:0006914autophagy-IEA-  
GO:0006935chemotaxis-TAS10570282  
GO:0007156homophilic cell adhesion via plasma membrane adhesion molecules-IEA-  
GO:0007165signal transduction-NAS10570282  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-TAS21035500  
GO:0007186G-protein coupled receptor signaling pathway-TAS21321382  
GO:0007411axon guidance-TAS-  
GO:0010508positive regulation of autophagy-TAS21321382  
GO:0010628positive regulation of gene expression-IMP25139353  
GO:0014065phosphatidylinositol 3-kinase signaling-IBA21873635  
GO:0014065phosphatidylinositol 3-kinase signaling-IMP25339672  
GO:0014065phosphatidylinositol 3-kinase signaling-TAS21321382  
GO:0016310phosphorylation-IDA25327288  
GO:0016477cell migration-IBA21873635  
GO:0016477cell migration-TAS21035500  21321382  
GO:0019221cytokine-mediated signaling pathway-TAS-  
GO:0030168platelet activation-IBA21873635  
GO:0030168platelet activation-TAS21035500  
GO:0033031positive regulation of neutrophil apoptotic process-IMP25339672  
GO:0036092phosphatidylinositol-3-phosphate biosynthetic process-IBA21873635  
GO:0036092phosphatidylinositol-3-phosphate biosynthetic process-IEA-  
GO:0038095Fc-epsilon receptor signaling pathway-TAS-  
GO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis-TAS-  
GO:0040016embryonic cleavage-IEA-  
GO:0046854phosphatidylinositol phosphorylation-IBA21873635  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0048010vascular endothelial growth factor receptor signaling pathway-TAS-  
GO:0048015phosphatidylinositol-mediated signaling-IBA21873635  
GO:0048015phosphatidylinositol-mediated signaling-TAS-  
GO:0050852T cell receptor signaling pathway-TAS-  
GO:0050900leukocyte migration-TAS-  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:0060055angiogenesis involved in wound healing-IEA-  
GO:0070527platelet aggregation-TAS21035500  
GO:2000369regulation of clathrin-dependent endocytosis-TAS21321382  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA-  
GO:0005730nucleolus-IDA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-IBA21873635  
GO:0005942phosphatidylinositol 3-kinase complex-IBA21873635  
GO:0016020membrane-IBA21873635  
GO:0030496midbody-IDA-  
KEGG ID KEGG Term
hsa00562Inositol phosphate metabolism
hsa04012ErbB signaling pathway
hsa04062Chemokine signaling pathway
hsa04070Phosphatidylinositol signaling system
hsa04150mTOR signaling pathway
hsa04210Apoptosis
hsa04370VEGF signaling pathway
hsa04380Osteoclast differentiation
hsa04510Focal adhesion
hsa04620Toll-like receptor signaling pathway
hsa04630Jak-STAT signaling pathway
hsa04650Natural killer cell mediated cytotoxicity
hsa04660T cell receptor signaling pathway
hsa04662B cell receptor signaling pathway
hsa04664Fc epsilon RI signaling pathway
hsa04666Fc gamma R-mediated phagocytosis
hsa04670Leukocyte transendothelial migration
hsa04722Neurotrophin signaling pathway
hsa04810Regulation of actin cytoskeleton
hsa04910Insulin signaling pathway
hsa04914Progesterone-mediated oocyte maturation
hsa04930Type II diabetes mellitus
hsa04960Aldosterone-regulated sodium reabsorption
hsa04973Carbohydrate digestion and absorption
hsa05100Bacterial invasion of epithelial cells
hsa05142Chagas disease (American trypanosomiasis)
hsa05145Toxoplasmosis
hsa05146Amoebiasis
hsa05160Hepatitis C
hsa05200Pathways in cancer
hsa05210Colorectal cancer
hsa05211Renal cell carcinoma
hsa05212Pancreatic cancer
hsa05213Endometrial cancer
hsa05214Glioma
hsa05215Prostate cancer
hsa05218Melanoma
hsa05220Chronic myeloid leukemia
hsa05221Acute myeloid leukemia
hsa05222Small cell lung cancer
hsa05223Non-small cell lung cancer
Reactome ID Reactome Term Evidence
R-HSA-109582HemostasisTAS
R-HSA-109704PI3K CascadeTAS
R-HSA-112399IRS-mediated signallingTAS
R-HSA-114604GPVI-mediated activation cascadeTAS
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-1266738Developmental BiologyTAS
R-HSA-1280215Cytokine Signaling in Immune systemIEA
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-1430728MetabolismTAS
R-HSA-1483255PI MetabolismTAS
R-HSA-1483257Phospholipid metabolismTAS
R-HSA-1500931Cell-Cell communicationIEA
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1660499Synthesis of PIPs at the plasma membraneTAS
R-HSA-166520Signaling by NTRKsTAS
R-HSA-168249Innate Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-168256Immune SystemIEA
R-HSA-186763Downstream signal transductionTAS
R-HSA-186797Signaling by PDGFTAS
R-HSA-187037Signaling by NTRK1 (TRKA)TAS
R-HSA-194138Signaling by VEGFTAS
R-HSA-194138Signaling by VEGFIEA
R-HSA-198203PI3K/AKT activationTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-202403TCR signalingTAS
R-HSA-202424Downstream TCR signalingTAS
R-HSA-202733Cell surface interactions at the vascular wallTAS
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisTAS
R-HSA-2029485Role of phospholipids in phagocytosisTAS
R-HSA-210993Tie2 SignalingTAS
R-HSA-2172127DAP12 interactionsTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-2404192Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)TAS
R-HSA-2424491DAP12 signalingTAS
R-HSA-2428924IGF1R signaling cascadeTAS
R-HSA-2428928IRS-related events triggered by IGF1RTAS
R-HSA-2454202Fc epsilon receptor (FCERI) signalingTAS
R-HSA-2730905Role of LAT2/NTAL/LAB on calcium mobilizationTAS
R-HSA-372790Signaling by GPCRTAS
R-HSA-373753Nephrin family interactionsIEA
R-HSA-388396GPCR downstream signallingTAS
R-HSA-392451G beta:gamma signalling through PI3KgammaTAS
R-HSA-397795G-protein beta:gamma signallingTAS
R-HSA-422475Axon guidanceTAS
R-HSA-4420097VEGFA-VEGFR2 PathwayTAS
R-HSA-4420097VEGFA-VEGFR2 PathwayIEA
R-HSA-449147Signaling by InterleukinsIEA
R-HSA-449147Signaling by InterleukinsTAS
R-HSA-451927Interleukin-2 family signalingTAS
R-HSA-512988Interleukin-3, 5 and GM-CSF signalingIEA
R-HSA-512988Interleukin-3, 5 and GM-CSF signalingTAS
R-HSA-556833Metabolism of lipidsTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-74751Insulin receptor signalling cascadeTAS
R-HSA-74752Signaling by Insulin receptorTAS
R-HSA-76002Platelet activation, signaling and aggregationTAS
R-HSA-8853659RET signalingTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA
R-HSA-912526Interleukin receptor SHC signalingTAS
R-HSA-912631Regulation of signaling by CBLIEA
R-HSA-912631Regulation of signaling by CBLTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29277178[Clinical Significance and Mechanism of PI3K p110beta Overexpression in Non-small Cell Lung Cancer]. (2017 Dec 20)Xiong YZhongguo Fei Ai Za Zhi